1. Molecular profiling for precision cancer therapies;Malone;Genome Med,2020
2. Accelerated approvals hit the target in precision oncology;Subbiah;Nat Med,2022
3. From tissue-agnostic to N-of-one therapies: (r)evolution of the precision paradigm;Adashek;Trends Cancer,2021
4. US Food and Drug Administration (FDA). FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors [press release]. 21 September, 2022, 〈https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors〉; 2022 [accessed 4 April, 2023].
5. Enabling precision oncology through precision diagnostics;Brown;Annu Rev Pathol,2020